News

CARLSBAD, CALIF. – May 11, 2009 – SkinMedica, Inc. today announced that it has entered into a co-promotion agreement with Allergan for ACZONE® (dapsone) Gel 5%, a first-in-class topical treatment for acne vulgaris. Representing the first new molecule in a decade approved by the FDA for the topical treatment of acne in patients 12 years of age and older, ACZONE® Gel 5% combines dapsone in a Solvent Microparticulate™gel, enabling dapsone to be applied topically in a well-tolerated formulation to provide patients with a convenient and effective therapy. Under the agreement, SkinMedica will exclusively promote ACZONE® Gel 5% to pediatricians in the United States through its existing sales force.

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced preliminary results from a pivotal anterior uveitis trial that compared Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% dosed four times daily (QID) to Pred Forte(R) (prednisolone acetate ophthalmic suspension) 1%, dosed eight times daily. Durezol is a topical ophthalmic corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery; it was approved by the US Food and Drug Administration in June 2008. Pred Forte(R) is the registered trademark of Allergan, Inc.

MALVERN, PA, Sep 17, 2008 (MARKET WIRE via COMTEX News Network) -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the first patients have been dosed in the Company's U.S. phase IIb trial of XIAFLEX(TM) for the treatment of Peyronie's disease. Peyronie's disease is the development of a collagen plaque, or scar tissue, on the shaft of the penis that hardens and reduces flexibility, causing the penis to bend or arc during erection resulting in psychological distress and pain for the patient and often interfering with or preventing intercourse.